top of page
Untitled design (34).png

OPTIMAL TREATMENT OF RETINAL DISEASE LEVERAGING NOVEL DELIVERY TECHNOLOGY

start
16.png
23.png
Everads: more effective, durable treatment for retinal diseases.
Our technology facilitates targeted, rapid delivery of therapy via the emerging suprachoroidal delivery route. Leveraging our technology, we are developing treatments to improve efficacy and reduce treatment burden, and also partnering with leading pharmaceutical and biotech companies to enable delivery of novel therapies using our technology.
About Everads
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology.  Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS)…. 
about
 Everads News

September 2023

Everads enters license agreement with Kriya Therapeutics for development of ocular gene therapy candidates using Everads' suprachoroidal delivery technology.

For Kriya's press release click here

For Everads' press release click here

Shutterstock_1946757709.jpg

June 2023

Everads is pleased to announce the publication in Translation Vision Sciences & Technology (TVST), an ARVO journal, of data showing that Everads’ suprachoroidal delivery technology enables safe, rapid and broad delivery throughout the posterior pole in non-human primate models. This work demonstrated that Everads’ technology was able to deliver 150-200 µL of ICG dye to the back of the eye via the suprachoroidal space. The injection was well tolerated in NHP eyes, with rapid distribution into the macular region and throughout the posterior pole. Moshe Weinstein, CEO of Everads, stated that “we are honored to have such a prestigious journal publish this promising data. Demonstrating the efficacy of this technology in non-human primates further confirms the promising results that can be achieved with our technology and we look forward to continuing its development with our collaborators”.

tvst 5_edited.jpg

May 2023

Everads’ invited to present at the 30th GoForIsrael Investment Conference.

Moshe Weinstein, CEO of Everads, presented the company at the GoForIsrael 2023 conference on May 3rd, 2023 in the innovative technologies in biotech session. This conference, in its 30th year, focuses on connecting between leading global investors and Israel’s most innovative technology companies. Organized by Cukierman & Co. and Catalyst Funds, GoforIsrael has been one of the most influential business conferences in Israel for over 25 years.

go for israel 4_edited_edited_edited_edited.jpg
Contact Us

Send us a message and we’ll get back to you shortly.

Thanks for submitting!

NEWS HOME
cntact form
bottom of page